<DOC>
	<DOCNO>NCT01884935</DOCNO>
	<brief_summary>The primary objective study determine pharmacokinetic ( PK ) profile multiple dose natalizumab pediatric subject relapsing-remitting multiple sclerosis ( RRMS ) . The secondary objective follow : characterize pharmacodynamic ( PD ) profile natalizumab ( define Î±4 integrin binding ) explore safety tolerability multiple dos natalizumab pediatric population .</brief_summary>
	<brief_title>PK PD Study Natalizumab Pediatric Subjects With RRMS</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key Rapidly evolve severe relapse remit multiple sclerosis , define 2 disabling relapse 1 year , 1 gadoliniumenhancing lesion brain MRI significant increase T2 lesion load , compare previous recent magnetic resonance imaging ( MRI ) Key History , abnormal laboratory value indicative , significant medical , neurologic ( MS ) , psychiatric disorder might preclude participation study opinion Investigator . Prior natalizumab therapy . NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Pediatric</keyword>
</DOC>